Virtu Financial LLC Has $247,000 Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Virtu Financial LLC lessened its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 31.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,512 shares of the company’s stock after selling 17,014 shares during the period. Virtu Financial LLC’s holdings in Recursion Pharmaceuticals were worth $247,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after buying an additional 4,626,268 shares during the period. Baillie Gifford & Co. grew its position in Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after acquiring an additional 2,522,132 shares during the last quarter. State Street Corp lifted its stake in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. FMR LLC increased its holdings in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Down 4.3 %

RXRX stock opened at $7.12 on Wednesday. The stock has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $7.23. The firm has a market capitalization of $2.04 billion, a PE ratio of -4.65 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.43) EPS. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,788 shares of company stock valued at $724,691 over the last three months. 15.75% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RXRX. Jefferies Financial Group cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.